Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX49 in Advanced/Metastatic Solid Tumors

12 november 2026 bijgewerkt door: Shanghai Henlius Biotech

A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HLX49 (Anti-HER2 Biparatopic and Bispecific ADC) in Participants With Advanced/Metastatic Solid Tumors

This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of HLX49 in patients with advanced/metastatic solid tumors.

Studie Overzicht

Gedetailleerde beschrijving

In the phase Ia of this study, an accelerated titration and 3 + 3 dose escalation method will be adopted, and the patients will be administered with HLX49 at different doses via intravenous infusion. The DLT observation period lasts for 3 weeks after the first administration of HLX49.

In phase Ib of this study, the Safety Review Committee will recommend dose groups for expansion based on the safety, efficacy, and PK data of the dose escalation phase. The dose expansion part will enroll patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) who have previously failed first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars. Patients will be randomized to receive different doses of HLX49 or the active comparator (trastuzumab deruxtecan, T-DXd).

Studietype

Ingrijpend

Inschrijving (Geschat)

222

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Willing and able to provide written informed consent and comply with the study protocol.
  2. Age: 18 to 75 years for Phase Ia; ≥ 18 years for Phase Ib. 3.Tumor Type & Prior Treatment: Phase Ia: Histologically or cytologically confirmed advanced or metastatic solid tumors that are refractory to standard treatment, or for which no standard treatment is available.

Phase Ib (GC/GEJC cohort): Histologically or cytologically confirmed advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) that has progressed during or after exactly one prior line of systemic therapy containing trastuzumab (or a biosimilar).

4.Confirmed HER2-positive status (Phase Ia: IHC 3+ or 2+; Phase Ib: IHC 3+ or IHC 2+/ISH+).

5.ECOG performance status score of 0 or 1. 6.At least one measurable lesion. 7.Life expectancy of more than 3 months. 8.Adequate washout period from prior treatments (e.g., at least 28 days for chemotherapy, radiotherapy, immunotherapy, or major surgery; at least 14 days for targeted therapy or hormone therapy) and recovery of previous treatment-related adverse events.

9.Must provide a tumor tissue sample for biomarker evaluation. 10.Adequate organ and bone marrow function as defined by protocol-specified laboratory tests.

11.Male and female participants with reproductive potential must agree to use highly effective contraception methods; female participants of childbearing potential must have a negative pregnancy test.

Exclusion Criteria:

  1. History of other malignant tumors within 2 years prior to the first dose (with exceptions for cured early-stage cancers like cervical carcinoma in situ or non-melanoma skin cancer).
  2. History of severe eye diseases (e.g., severe keratopathy or moderate to severe dry eye).
  3. History of or current interstitial lung disease (ILD) or non-infectious pneumonitis requiring systemic steroids.
  4. Severe allergic reactions to monoclonal antibodies or allergy to any component of the investigational product.
  5. Active systemic infections requiring intravenous antibiotics.
  6. Requirement for treatment with systemic corticosteroids or other immunosuppressive medications within 2 weeks prior to the first dose.
  7. Clinically significant cardiovascular diseases, including but not limited to: severe/unstable angina, myocardial infarction within 6 months, symptomatic congestive heart failure, LVEF <50%, poorly controlled hypertension, or clinically significant prolonged QTc interval.
  8. Symptomatic or uncontrolled brain or meningeal metastases, or spinal cord compression.
  9. Active or suspected autoimmune diseases (exceptions apply for well-controlled type 1 diabetes and autoimmune hypothyroidism on replacement therapy).
  10. Unhealed major wounds or anticipation of major surgery during the study.
  11. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage.
  12. Use of strong CYP3A inhibitors or inducers within 2 weeks prior to the first dose.
  13. Active tuberculosis.
  14. Known history of immunodeficiency, including HIV, or history of solid organ transplantation.
  15. Active Hepatitis B (HBV) or Hepatitis C (HCV) infection (exceptions apply for stable/controlled HBV or HCV meeting specific viral load criteria).
  16. Pregnant or breastfeeding females.
  17. Subjects who are assessed as unsuitable for participating in this clinical study due to any clinical or laboratory abnormalities or other reasons by the investigator.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Ia (Dose Escalation)

Patients with advanced/metastatic solid tumors, who are refractory to standard treatment or for which no standard treatment is available.

Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).

Experimenteel: Ib HLX49 Dose 1 (Dose Expansion)

Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.

Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).

Experimenteel: Ib HLX49 Dose 2 (Dose Expansion)

Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.

Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).

Experimenteel: Ib HLX49 Dose 3 (Dose Expansion)

Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.

Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).

Actieve vergelijker: Ib Trastuzumab deruxtecan (Dose Expansion)

Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.

Patients with good tolerability and well controlled disease will receive Trastuzumab deruxtecan via intravenous infusion once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
The Dose-Limiting Toxicity (DLT) of HLX49 within 21 days after the first Administration
Tijdsspanne: From first dose to the end of Cycle 1 (each cycle is 3 weeks).

DLT refers to the AEs that are determined to be related to the investigational product by the investigator, whose severity will affect the escalation of dose level. In this study, the DLT observation period lasts for 3 weeks (21 days) after the first administration of HLX49.

From first dose to the end of Cycle 1 (each cycle is 3 weeks).
The maximum tolerated dose (MTD) of HLX49
Tijdsspanne: From first dose to the end of Cycle 1 (each cycle is 3 weeks).

The highest dose level, at which DLT is observed in no more than one of 6 evaluable patients, is defined as MTD of HLX49.

From first dose to the end of Cycle 1 (each cycle is 3 weeks).
RP2D
Tijdsspanne: Approximately up to 24 months.

The recommended phase 2 dose (RP2D) of HLX49 in participants with advanced/metastatic gastric/gastroesophageal junction adenocarcinoma.

Approximately up to 24 months.
Objective response rate (ORR) assessed by IRRC
Tijdsspanne: Approximately up to 24 months.

Percentage of participants with complete response (CR) and partial response (PR) based on independent radiographic review committee (IRRC) assessment.

Approximately up to 24 months.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Objective response rate (ORR)
Tijdsspanne: Approximately up to 24 months.

Percentage of participants with complete response (CR) and partial response (PR) based on investigator assessment.

Approximately up to 24 months.
Duration of response (DOR)
Tijdsspanne: Approximately up to 24 months.

Length of time response continued based on investigator and IRRC assessment.

Approximately up to 24 months.
Progression-free survival (PFS)
Tijdsspanne: Approximately up to 24 months.

The PFS is defined as the time from the date of enrollment to the date of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause, whichever occurred first.

Approximately up to 24 months.
Overall survival (OS)
Tijdsspanne: Approximately up to 24 months.

Time from the date of enrollment to the date of death for any cause.

Approximately up to 24 months.
Cmax
Tijdsspanne: Up to 21 days after the first dose.

Maximum serum concentration (Cmax) of HLX49, total antibody, and free payload.

Up to 21 days after the first dose.
Tmax
Tijdsspanne: Up to 21 days after the first dose.

Time to maximum serum concentration (Tmax) of HLX49, total antibody, and free payload.

Up to 21 days after the first dose.
T1/2
Tijdsspanne: Up to 21 days after the first dose.

Elimination half-life (t1/2) of HLX49, total antibody, and free payload.

Up to 21 days after the first dose.
ADA (anti-drug antibody)
Tijdsspanne: Approximately up to 24 months.

Positive rate of anti-HLX49 antibodies (ADA).

Approximately up to 24 months.
NAb (neutralizing antibody)
Tijdsspanne: Approximately up to 24 months.

Positive rate of neutralizing antibodies (NAb) against HLX49.

Approximately up to 24 months.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 november 2026

Primaire voltooiing (Geschat)

1 december 2029

Studie voltooiing (Geschat)

1 december 2030

Studieregistratiedata

Eerst ingediend

12 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

12 november 2026

Eerst geplaatst (Werkelijk)

18 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

12 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • HLX49-FIH101

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren